[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

de Jong, M; Breeman, W A; Bernard, B F; Bakker, W H; Schaar, M; van Gameren, A; Bugaj, J E; Erion, J; Schmidt, M; Srinivasan, A; Krenning, E P

de Jong, M; Breeman, W A; Bernard, B F; Bakker, W H; Schaar, M; van Gameren, A; Bugaj, J E; Erion, J; Schmidt, M; Srinivasan, A; Krenning, E P.

Affiliation

de Jong M; Department of Nuclear Medicine, University Hospital and Erasmus University Rotterdam, 3015 GD Rotterdam, The Netherlands. dejong@nuge.azr.nl

Int J Cancer ; 92(5): 628-33, 2001 Jun 01.

Article in En | MEDLINE | ID: mdl-11340564

Subject(s)

Lutetium/therapeutic use; Octreotide/analogs & derivatives; Pancreatic Neoplasms/radiotherapy; Radioisotopes/therapeutic use; Receptors, Somatostatin/analysis; Animals; Autoradiography; Chelating Agents/therapeutic use; Kidney/metabolism; Male; Octreotide/therapeutic use; Pancreatic Neoplasms/metabolism; Pancreatic Neoplasms/mortality; Radiotherapy Dosage; Rats; Rats, Inbred Lew; Survival Rate; Tissue Distribution

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Radioisotopes / Octreotide / Receptors, Somatostatin / Lutetium Limits: Animals Language: En Journal: Int J Cancer Year: 2001 Type: Article Affiliation country: Netherlands

Search on Google

XML

PubMed Links